Innospec Q2 revenue beats estimates

Innospec

05/08/2025 21:55

Overview

Innospec Q2 rev rises 1% to $439.7 mln, beating analyst expectations

Adjusted EPS for Q2 just misses analyst estimates at $1.26, per LSEG data

Co repurchased $8.2 mln in shares, maintaining a debt-free balance sheet

Outlook

Innospec expects no Latin America activity resumption this year

Companyexpects sequential gross margin improvement in Performance Chemicals in the coming quarters

Innospec sees continued strong results in Fuel Specialties

Company aims for sequential operating income growth in Oilfield Services

Result Drivers

FUEL SPECIALTIES - Strong growth in operating income despite revenue decline, driven by improved price/mix and positive currency impact

PERFORMANCE CHEMICALS - Revenue growth driven by lower margin products, leading to decreased gross margins and operating income

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$439.70 mln
$439.10 mln (3 Analysts)
Q2 Adjusted EPS
Miss
$1.26
$1.27 (3 Analysts)
Q2 EPS
$0.94
Q2 Net Income
$23.50 mln
Q2 Gross Profit
$123.20 mln
Q2 Operating Income
$34.30 mln
Q2 Pretax Profit
$31.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the specialty chemicals peer group is "buy"

Wall Street's median 12-month price target for Innospec Inc is $115.00, about 31% above its August 4 closing price of $79.35

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nGNXw3ldF

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)